Efficacy News and Research

RSS

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Improving vaccination rates in boys plays a crucial role against HPV infection

Improving vaccination rates against the human papillomavirus (HPV) in boys is key to protecting both men and women, says new research from University of Toronto Professor Peter A. Newman from the Factor-Inwentash Faculty of Social Work.

23 Jul 2013

Chinese herbal medicine appears to be an effective treatment for vascular dementia

Chinese herbal medicine, which has been used for thousands of years in China, has long been considered an effective treatment for vascular dementia. There are already meta-analyses of the effects of herbal extracts (ginkgo biloba and huperzine A) on vascular dementia.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of stimulating the brain during sleep to treat movement disorder symptoms.

22 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Teduglutide offers relief for patients with short-bowel syndrome

A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when it's exposed to the real thing.

19 Jul 2013

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Computerized cognitive testing is increasingly playing a key role in therapy development for dementia and Alzheimer's disease. This week at the Alzheimer's Association International Conference, Keith Wesnes Ph.D., Practice Leader of Bracket and founder of the CDR System-, discussed new data for novel therapies at two poster presentations at the Alzheimer's Association International Conference.

19 Jul 2013

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

University of Arizona researchers have found in a recent study that ultrasound waves applied to specific areas of the brain appear able to alter patients' moods. The discovery has led the scientists to conduct further investigations with the hope that this technique could one day be used to treat conditions such as depression and anxiety.

19 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Creating and promoting foods that contain natural inhibitors of unhealthy angiogenesis - the formation of blood vessels that feed and promote disease, obesity and inflammation - is the "new frontier in dietary health," according to a presentation at the 2013 Institute of Food Technologists Annual Meeting & Food Expo- in Chicago.

18 Jul 2013

Efficacy News and Research

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Improving vaccination rates in boys plays a crucial role against HPV infection

Chinese herbal medicine appears to be an effective treatment for vascular dementia

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Great Lakes NeuroTechnologies receives patent for Parkinson’s disease monitoring technology

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Teduglutide offers relief for patients with short-bowel syndrome

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News